#EndoSky#LiverSky
LightNews LightNews
rnflex.bsky.social
Hey y'all. Need serious help, trying to find oncology care recommendations for a family member. Either in Michigan or Orange County Cali. Probable S3 Pancreatic head Ca w/ Mets to liver, (biopsy pending) #liversky #endosky #oncosky

Any help would be greatly appreciated 🙏
February 20, 2025 at 7:18 PM
thelancetendo.bsky.social
Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment www.thelancet.com/journals/lan...
#MASLD
#OpenAccess
#MedSky #EndoSky #LiverSky #HepSky
Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment
The global epidemic of metabolic dysfunction-associated steatotic liver disease (MASLD) is increasing worldwide. People with MASLD can progress to cirrhosis and hepatocellular carcinoma and are at inc...
www.thelancet.com
August 1, 2025 at 1:57 PM
thelancetendo.bsky.social
Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment
www.thelancet.com/journals/lan...
#MASLD #MASH #CVD #obesity #T2D #dyslipidaemia
#OpenAccess
#MedSky #EndoSky #LiverSky #HepSky
March 7, 2025 at 10:03 AM
thelancetendo.bsky.social
People with #MASLD can progress to cirrhosis and hepatocellular carcinoma and are at increased risk of developing type 2 diabetes, cardiovascular disease, chronic kidney disease, and extrahepatic cancers www.thelancet.com/journals/lan...
#OpenAccess

#MedSky #EndoSky #LiverSky #HepSky
August 14, 2025 at 10:54 AM
robbrierley.bsky.social
Our Editorial this month discusses the buzz around incretin mimetics and their role in tackling the obesity critis, stressing the need for their integration into broader public health initiatives

www.thelancet.com/journals/lan...

#GastroSky #LiverSky #MedSky #EndoSky #obesity
Quote from Editorial - "The excitement surrounding incretin mimetics is understandable, but, on their own, these drugs will not end the obesity crisis"
November 15, 2024 at 11:45 AM
thelancetendo.bsky.social
Insulin resistance unrelated to #obesity is a characteristic pathophysiological component of type 2 #diabetes and is closely related to the development of atherosclerotic cardiovascular disease www.thelancet.com/journals/lan...
#T2D #ASCVD
#MedSky #EndoSky #LiverSky
Managing insulin resistance: the forgotten pathophysiological component of type 2 diabetes
Glucagon-like peptide-1 (GLP-1) receptor agonists have gained widespread use in the treatment of individuals with type 2 diabetes because of their potent weight loss promoting effect, ability to augme...
www.thelancet.com
April 16, 2025 at 1:09 PM
lancetgastrohep.bsky.social
New @thelancet.com - Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study

www.thelancet.com/journals/lan...

#LiverSky #MedSky #EndoSky
Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study
Pemvidutide treatment met the primary endpoint of MASH resolution without worsening of fibrosis at 24 weeks but did not meet the other primary endpoint of fibrosis improvement without worsening of MAS...
www.thelancet.com
November 12, 2025 at 7:59 AM
thelancetendo.bsky.social
"In accordance with WHO principles of screening for disease, we believe consideration should be given to the effect of screening for #MASLD #fibrosis in all patients with #prediabetes or type 2 #diabetes on health service capacity" www.thelancet.com/journals/lan... #T2D

#MedSky #EndoSky #LiverSky
Type 2 diabetes, prediabetes, and MASLD: who and when to screen and how to treat?
In 2023, consensus was reached that a diagnosis of metabolic dysfunction-associated steatotic liver disease (MASLD)1 could be assigned if a person showed evidence of hepatic steatosis with no aetiolog...
www.thelancet.com
June 25, 2025 at 12:36 PM
thelancetendo.bsky.social
People with #MASLD can progress to cirrhosis and hepatocellular carcinoma and are at increased risk of developing type 2 #diabetes, #cardiovascular disease, chronic #kidney disease, and extrahepatic #cancers www.thelancet.com/journals/lan...
#T2D #CVD #CKD
#OpenAccess

#MedSky #EndoSky #LiverSky
September 6, 2025 at 10:51 AM
thelancetendo.bsky.social
There is substantial heterogeneity in the contributors to the pathophysiology of #MASLD, which might influence its rate of progression, its relationship with #cardiometabolic diseases, and the response to therapy www.thelancet.com/journals/lan...
#OpenAccess

#MedSky #EndoSky #LiverSky #HepSky
October 10, 2025 at 12:47 PM
thelancetendo.bsky.social
New—Type 2 #diabetes, #prediabetes, and #MASLD: who and when to screen and how to treat? thelancet.com/journals/lan... #T2D

#MedSky #EndoSky #LiverSky #HepSky #GastroSky
Type 2 diabetes, prediabetes, and MASLD: who and when to screen and how to treat?
In 2023, consensus was reached that a diagnosis of metabolic dysfunction-associated steatotic liver disease (MASLD)1 could be assigned if a person showed evidence of hepatic steatosis with no aetiolog...
thelancet.com
June 19, 2025 at 10:35 PM
thelancetendo.bsky.social
People with #MASLD can progress to cirrhosis & hepatocellular carcinoma & are at increased risk of developing type 2 #diabetes, #cardiovascular disease, chronic #kidney disease, & extrahepatic #cancers www.thelancet.com/journals/lan...
#T2D #CVD #CKD #obesity
#OpenAccess

#MedSky #EndoSky #LiverSky
May 7, 2025 at 1:00 PM
thelancetendo.bsky.social
Type 2 #diabetes, #prediabetes, and #MASLD: who and when to screen and how to treat? www.thelancet.com/journals/lan... #T2D

#MedSky #EndoSky #LiverSky #GastroSky
Type 2 diabetes, prediabetes, and MASLD: who and when to screen and how to treat?
In 2023, consensus was reached that a diagnosis of metabolic dysfunction-associated steatotic liver disease (MASLD)1 could be assigned if a person showed evidence of hepatic steatosis with no aetiolog...
www.thelancet.com
July 19, 2025 at 2:06 PM
thelancetendo.bsky.social
Read our August Issue, featuring multiple endocrine neoplasia type 1 (MEN1), thyroid function and autoimmunity, gestational diabetes, type 1 diabetes, type 2 diabetes, MASLD, older adults, obesity, MEN2B, and more bit.ly/2LArJXX

#MedSky #EndoSky #OncSky #LiverSky #HepSky #WomensHealthSky
July 16, 2025 at 12:48 PM
thelancetendo.bsky.social
We propose that drug-induced weight loss is largely responsible for the reported improvements in osteoarthritis, obstructive sleep apnoea, and metabolic dysfunction-associated steatohepatitis outcomes www.thelancet.com/journals/lan...
#weightloss #GLP-1 receptor agonists

#MedSky #EndoSky#LiverSky
Estimating direct tissue effects versus weight loss effects of incretin-based drugs for obesity on various chronic conditions
The extent to which newer, incretin-based drugs for obesity improve disease outcomes via weight loss versus the direct effects of these drugs is the subject of intense interest. Although reductions in...
www.thelancet.com
August 24, 2025 at 9:31 AM
robbrierley.bsky.social
Combining Retinal Scanning and Liver Screening in T2D

www.medscape.com/viewarticle/... via @medscape.bsky.social

#LiverSky #MedSky #EndoSky
Combining Retinal Scanning and Liver Screening in T2D
A novel screening approach combining liver examination with retina scanning showed high acceptance among patients with type 2 diabetes, even though false-positive results were common.
www.medscape.com
December 24, 2024 at 2:48 PM
thelancetendo.bsky.social
There is substantial heterogeneity in the contributors to the pathophysiology of #MASLD, which might influence its rate of progression, its relationship with #cardiometabolic diseases, and the response to therapy www.thelancet.com/journals/lan...
#OpenAccess
#MedSky #EndoSky #CardioSky #LiverSky
April 12, 2025 at 11:22 AM
thelancetendo.bsky.social
People with #MASLD can progress to cirrhosis and hepatocellular carcinoma & are at increased risk of developing type 2 #diabetes, #cardiovascular disease, chronic #kidney disease, & extrahepatic #cancers www.thelancet.com/journals/lan...
#MASLD #MASH
#OpenAccess
#MedSky #EndoSky #LiverSky #HepSky
March 18, 2025 at 7:45 AM
lancetgastrohep.bsky.social
New @ebiomedicine.bsky.social - An inhibitory GLP-1 circuit in the lateral septum modulates reward processing and alcohol intake in rodents

www.thelancet.com/journals/ebi...

#LiverSky #EndoSky #MedSky
An inhibitory GLP-1 circuit in the lateral septum modulates reward processing and alcohol intake in rodents
This study provides new insights into how GLP-1R agonists may reduce alcohol intake. Overall, the findings underscore the potentially inhibitory neuromodulatory role of LS GLP-1R in regulating alcohol...
www.thelancet.com
April 22, 2025 at 7:55 AM